Roflumilast
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Roflumilast: Repurposing Potential Under Review — TxGNN Predictions Pending
One-Sentence Summary
Roflumilast (DrugBank: DB01656) is a selective phosphodiesterase-4 (PDE4) inhibitor approved for the management of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis, and is marketed in the United Kingdom as Daxas. This Evidence Pack is critically incomplete: no TxGNN repurposing predictions have been generated, UK regulatory data was not captured in the structured fields, and key safety information is absent. A full repurposing evaluation cannot be issued at this stage; the recommended decision is Hold pending resolution of the two identified data gaps (DG001, DG002).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Severe COPD associated with chronic bronchitis (known from external sources; not captured in current Evidence Pack structured fields) |
| Predicted New Indication | Pending — TxGNN prediction pipeline has not been executed for this drug |
| TxGNN Prediction Score | Pending |
| Evidence Level | Cannot be determined |
| UK Market Status | Data collection incomplete — Evidence Pack records 0 licences; however, Roflumilast is known to hold MHRA marketing authorisation (Daxas) |
| Number of Marketing Authorisations | 0 recorded in current data (likely a data collection error — see above) |
| Recommended Decision | Hold |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for Roflumilast (DB01656) contains two identified data gaps — one classified as Blocking (DG001: MHRA SmPC warnings and contraindications) and one as High (DG002: mechanism of action) — and, critically, the TxGNN prediction pipeline has not been run for this drug, meaning there are no repurposing candidates to evaluate.
To proceed, the following is needed:
- Run the TxGNN prediction pipeline: Execute both the knowledge graph (KG) and deep learning (DL) prediction methods for Roflumilast (DB01656) against the current disease vocabulary to generate ranked repurposing candidates with confidence scores.
- Collect UK regulatory data: Retrieve MHRA marketing authorisation records for Daxas (roflumilast) to confirm licence numbers (PL), approved indications, dosage forms, and current market status — the zero-licence figure in the current Evidence Pack appears to reflect a data collection failure rather than actual market absence.
- Populate mechanism of action (DG002): Query the DrugBank API for DB01656 to document the selective PDE4 inhibitor MOA, including subtype selectivity (PDE4B preference), downstream cAMP pathway effects, and known anti-inflammatory targets relevant to repurposing analysis.
- Obtain safety data (DG001): Download and parse the current UK SmPC for Daxas from the MHRA product information portal to populate warnings (including psychiatric events, weight loss), contraindications, and drug interaction data.
- Regenerate the Evidence Pack: Once all gaps above are resolved, regenerate a complete Evidence Pack (v5+) and resubmit for a full repurposing evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.